Lexicon Pharmaceuticals, Novo Nordisk strike obesity-drug license deal worth up to $1B
Lexicon Pharmaceuticals Inc. (Nasdaq: LXRX) said March 28 it will exclusively license its drug candidate LX9581 to Danish pharmaceutical giant Novo Nordisk A/S (NYSE: NVO). Under the terms of the agreement, Lexicon will receive up to $1 billion in up-front and potential development-, regulatory- and sales-milestone payments.
This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...
Novo Nordisk is expanding its prospects in obesity and other metabolic disorders by securing rights to an early-clinical engineered peptide whose effects comes from activating three receptors ...
March 24 (Reuters) - Danish drugmaker Novo Nordisk (NOVOb.CO), opens new tab ... strengthen its foothold in the potential $150 billion obesity market through the development of next-generation ...
Novo Nordisk announced Monday a $2 billion deal ... outside of China that is in early-stage development to treat obesity, Type 2 diabetes and other diseases. The candidate, currently called ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback